SERCEB Southeast Regional Centers of Excellence for Bio*

SERCEB 东南区域生物卓越中心*

• 批准号: 7560471
• 负责人: PHILIP Frederick SPARLING
• 金额: --
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-04 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7560471
• 关键词: Anthrax disease; Antibodies; Antigens; Bacillus anthracis; Biological; Biosensor; Centers for Disease Control and Prevention (U.S.); Collaborations; Complex; Computational Biology; Computer Systems Development; Crystallography; Data Analyses; Data Set; Detection; Development; Diagnostic; Diagnostic tests; Environment; Florida; Francisella tularensis; Genomics; Goals; Grant; Guanosine Monophosphate; Immune response; Immunologic Monitoring; Immunology; Infection; Infectious Agent; Institution; Laboratories; Ligands; Molecular; Monoclonal Antibodies; Nanotechnology; National Institute of Allergy and Infectious Disease; Natural Immunity; Orthopoxvirus; Pathogenesis; Patients; Phage Display; Pharmaceutical Preparations; Proteins; Proteome; Proteomics; Research; Research Institute; Research Personnel; Rift Valley fever virus; Science; Screening procedure; Sequence Analysis; Serotherapies; Speed; Staging; T-Lymphocyte Epitopes; Techniques; Technology; Therapeutic; Toxin; United States National Institutes of Health; Universities; Vaccine Design; Vaccine Production; Vaccine Research; Vaccines; Work; Yersinia pestis; acquired immunity; base; biodefense; citrate carrier; drug development; drug discovery; genome sequencing; innovation; novel; novel vaccines; prognostic; programs; protein expression; response; small molecule; structural biology; technology development; vaccine development

DESCRIPTION (provided by applicant): The Region IV RCE is the Southeastern Regional Center of Excellence in Emerging Infections and Biodefense or SERCEB. SERCEB has unified the major research institutions in Region IV, and has established collaborations with Oak Ridge National Laboratory in Oak Ridge, TN, the Centers for Disease Control and Prevention, Atlanta, GA, and the Vaccine Research Center at the NIH. The goals of SERCEB are to develop new vaccines, therapeutics, and diagnostics to better protect the nation against potential bioterrorist threats. This will be accomplished by interdisciplinary and collaborative research using cutting edge science. A major research focus is on novel vaccine development for orthopoxviruses, Bacillus anthracis and Yersinia pestis, with each program led by a team of internationally renowned investigators (Programs 1, 3, 4, and 5). Two immunology programs will interact synergistically with the vaccine programs: Program 6 will develop strategies to modulate innate immunity to enhance immune responses to select agents and vaccines, and Program 7 will develop strategies to enhance adaptive T and B immune responses to select agents and vaccines. New drug development will include rapid screening of existing compounds and development of entirety novel drugs against orthopoxviruses (Program 2), as well as therapeutics directed at innate immunity (Program 6), Anthrax (Program 5), and Yersinia pestis (Program 4). Multiple sophisticated cores will provide powerful assistance for development of vaccines, drugs, and diagnostics. SERCEB also will help to bring new investigators to the biodefense effort, through a combination of educational programs, support of innovative new projects, and synergistic interactions among some of the best investigators in relevant research in the nation.

描述（由申请人提供）：区域IV RCE是东南地区新兴感染和生物防御卓越中心或SERCEB。SERCEB已经统一了第四区的主要研究机构，并与田纳西州橡树岭的橡树岭国家实验室、佐治亚州亚特兰大的疾病控制和预防中心以及NIH的疫苗研究中心建立了合作关系。SERCEB的目标是开发新的疫苗，治疗和诊断，以更好地保护国家免受潜在的生物恐怖主义威胁。这将通过使用尖端科学的跨学科和合作研究来实现。一个主要的研究重点是针对正痘病毒、炭疽杆菌和鼠疫耶尔森菌的新型疫苗开发，每个项目都由一个国际知名的研究人员团队领导（项目1、3、4和5）。两个免疫学项目将与疫苗项目协同作用：项目6将开发调节先天免疫的策略，以增强对选定药剂和疫苗的免疫应答，项目7将开发增强对选定药剂和疫苗的适应性T和B免疫应答的策略。新药开发将包括现有化合物的快速筛选和针对正痘病毒的全新药物的开发（项目2），以及针对先天免疫（项目6）、炭疽（项目5）和鼠疫耶尔森菌（项目4）的治疗药物。多个复杂的核心将为疫苗，药物和诊断的开发提供强大的帮助。SERCEB还将通过教育计划、支持创新性新项目以及全国相关研究中一些最优秀的研究人员之间的协同互动，帮助新的研究人员参与生物防御工作。